TorreyPines Therapeutics Initiates Clinical Trial To Evaluate Analgesic Effect Of Oral Prodrug Of Tezampanel TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) announced it has initiated a clinical trial to evaluate the analgesic effect of NGX426, the oral prodrug of its lead product candidate, tezampanel. The randomized, double-blind, placebo-controlled Phase I trial will enroll 18
healthy volunteers at a single center in the United States.
Source: www.medicalnewstoday.comABMC Receives FDA Clearance Of Its Rapid TOX Cup(R) American Bio Medica Corporation (NASDAQ:ABMC) announced that the US Food and Drug Administration (FDA) has granted the Company 510(k) clearance on its Rapid TOX Cup, a patent pending drug screen in an all-inclusive cup platform. The clearance allows ABMC to provide the Rapid TOX Cup to customers in clinical markets.
Source: www.medicalnewstoday.comLabels: No Prescription, Online Pharmacy
# posted by Network @ 6:01 AM
